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Introduction 
It is estimated that approximately 88,750 new cases 
of gynecologic malignancies were diagnosed in 
2012 with approximately 32,500 deaths (1). Fifteen 
to 21% of these women will be less than 40 years of 
age at the time of diagnosis (2). 
With the continuous trend in delayed childbearing 
age, some patients have a strong desire for future 
child bearing, and others may wish to preserve their 
ovarian function only and have the option for 
adoption as well. Unfortunately preservation of 
reproductive function cannot be offered to every 
eligible patient for various reasons including 
unfamiliarity, lack of knowledge, financial and 
psychosocial constrains. 
An increasing number of patients, particularly 
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Abstract  
Objective: The aim of this paper is to present an overview of available published methods for preservation of ovarian function and 
fertility in young patients with gynecologic malignancies who desire to maintain their child-bearing capacity or ovarian function.  
Methods: A Medline search was conducted and published articles from American and European studies from 1984 to present were 
reviewed. The effect of cancer treatment on reproductive capacity and different methods of fertility preservation with their 
reproductive outcomes and ovarian function and long term side effects are presented. 
Results: The pregnancy rate in patients with gynecologic malignancies varies according to the type of the malignancy, stage of 
disease, treatment modalities, and other factors such as patient’s age and reproductive capacity, status of sexual partner, and 
potential for surrogacy. The highest success rates of pregnancy have been reported in patients who had fertility-sparing surgery 
and utilized assisted reproduction technology. 
Conclusion: Today, higher cure rates and longer survival are a result of early cancer detection and treatment. In conjunction with 
the advances in assisted reproduction and fertility , the preservation of ovarian function and fertility has become a major part of 
contemporary patient care and should be offered to any young patient with gynecologic cancer. These alternative options are 
appropriate only in highly selective patients with good prognoses. A multidisciplinary approach and collaboration between other 
related disciplines might optimize a successful outcome in these patients. 
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those younger than 40 years old, are confronted with 
the consequences of cancer treatment, particularly 
radiation and chemotherapy, which can have 
significant impact not only on the ovarian function 
and fertility, but also long term deleterious effects of 
menopause (3-5).  
Several strategies have been explored for 
preservation of ovarian function and fertility. 
Recently, there has been a tendency towards less radical 
approaches for treatment of cervical cancer in young 
women. Loop excision technique or cervical conization 
are increasingly being recommended for very early stage 
cervical cancer and more recently radical trachelectomy 
which is a less radical procedure and the uterus can be 
preserved for future fertility (6, 7). 
Ovarian transposition has been utilized in patients with 
locally advanced cervical cancer. The aim is to surgically 
remove the ovaries from the direct field of radiation. Most 
ovarian transpositions currently are carried out 
laparoscopically, and there have been suggestions that 
lateral transposition may be more protective than median 
transposition of ovaries (8, 9).  
Endometrial cancer is usually a disease of the 
postmenopausal group and is rare in women under the age 
of 40 (www.cancer.org). The treatment commonly 
involves total hysterectomy and bilateral oophorectomy. 
Although the standard treatment for women with complex 
atypical endometrial hyperplasia is hysterectomy, 
hormonal therapy may be recommended for young 
patients who have not completed their family and have a 
desire for future childbearing (10).  
Epithelial ovarian cancer continues to be treated radically 
with loss of reproductive organs .Germ cell ovarian 
tumors, sex cord-stromal tumors, borderline tumors of 
the ovary (low malignant potential) and stage IA invasive 
epithelial ovarian cancer can be treated with more 
conservative (fertility-sparing) surgeries. These types 
of surgical procedures include, ovarian cystectomy 
or unilateral salpingo-oophorectomy, with or without 
hysterectomy, are often adequate treatment (11-14).  
Cervical cancer 
The standard treatment for patients with early, 
locally invasive cervical cancer had been some form 
of radical hysterectomy and bilateral pelvic with or 
without paraaortic lymphadenectomy. Radiation or 
chemo-radiation has been utilized for those with 
locally advanced or metastatic disease. However, 
there are several alternative options for young 
patients with early stage disease who desire to 
preserve their ovarian function and fertility without 
compromising their cure. 
Conization Cervical Conization is recommended 
for young patients with stage IA1 (stromal 
invasion≤ 3 mm and extension <7mm) with no 
lympho-vascular invasion in whom the risk of nodal 
metastasis or recurrence is minimal. The reported 
survival at 5 years was 98% (95% CI 96-99%) for 
patients who had hysterectomy and 99% (95% CI 
97-99%) for those who had Conization (15).  
Simple Trachelectomy 
In recent years several retrospective studies have 
shown a low incidence (< 1%) of parametrial 
involvement in patients with early stage (IA2, IB1) 
cervical cancer with favorable pathologic 
characteristics. In addition, in approximately 60% of 
patients undergoing radical trachelectomy, the final 
pathologic specimen after a diagnostic cone did not 
have any residual disease (16-19).  
Currently, a prospective, multi-center, international 
cohort study is being conducted evaluating the outcome of 
performing pelvic lymphadenectomy with conservative 
surgery (simple hysterectomy or conization) in patients 
with favorable pathologic characteristics. The inclusion 
criteria includes patients with stage IA2 or IB1disease; 
tumor size ≤ 2cm; and squamous or adenocarcinoma 
histology without lymphovascular invasion (20). 
Radical Trachelectomy. This procedure can be 
performed vaginally, abdominally or robotically with 
pelvic with or without para aortic lymphadenectomy 
(21). Radical trachelectomy may be recommended in 
stage IA1 disease with lymphovascular invasion, 
stage IA2, or stage IB1 with small tumor size 
(<2cm) in the absence of high risk histological 
features (e.g. clear cell, small cell neuroendocrine 
type, and glassy cell tumors) and no evidence of 
nodal metastasis (22). Successful pregnancies have 
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been reported following radical trachelectomy 
( Table 1 ). There were 77 fetal losses and 181 births 
among cumulative of 258 patients who underwent 
radical trachelectomy (23-28). Shepherd et al (29) 
reported on a total of 123 radical vaginal 
trachelectomies, of which a 5 year cumulative 
pregnancy rate was 52.8%. Rate of pregnancy loss 
and premature birth was 12.7% and 25%, 
respectively. Jolly et al (30), in a literature review, 
reported an overall conception rate of 40% following 
radical trachelectomy , with rates of preterm and 
term deliveries of 25% and 42% respectively. In 
cases of pregnancy loss, the overall rate of first 
trimester pregnancy loss was 19% comparable to 
that of general population. The rate of second 
trimester loss was 9.5% and elective termination rate 
of 3.5% .These findings were in agreement to those 
reported by Plante et al (31) and Alexander-Sefre et 
al (32). 
In a more recent review article, Schneider et al (33), 
reported, the overall recurrence rate after vaginal 
trachelectomy was 3% to 6% and the death rate was 2% to 
5% when the tumor size was no larger than 2 cm in 
diameter. The fertility did not decrease, but the risk for 
premature delivery was 2 to 3 times higher compared to 
women with an intact cervix. In this cohort 50% of 
women delivered beyond 37 weeks, whereas 21%-28% 
delivered prematurely before 37 weeks and 12% of 
patients delivered before 32 weeks. Long term 
morbidity associated with radical trachelectomy 
includes vaginal discharge, dysmenorrhea, irregular 
bleeding, and complication of cervical suture such 
as isthmic stenosis, and prolonged amenorrhea. 
Recent reviews of radical vaginal trachelectomy 
reported, over all tumor recurrence rate of < 5% 
(4.2-5.3%) and a death rate of <3% (2.5-3.2%) 
(34,35). These results are comparable to those of 
radical hysterectomy for similar size lesions (36). 
Neo-adjuvant chemotherapy has been used to 
reduce the tumor size in patient with >2cm lesion 
prior to fertility- sparing surgery. 
Maneo et al (37) reported their experience with 21 
stage IB1 cervical cancer patients. Median tumor 
size was 1.5 cm (1.0-3.0 cm) and patients were 
treated with neo-adjuvant chemotherapy followed by 
cold knife conization and pelvic lymphadenectomy. 
Complete pathologic response was observed in 
5(24%), and residual in situ or microinvasive disease 
was present in 12(14%) patients. Nine patients 
(43%) had stromal invasion between 1-3 mm, and 4 
patients (19%) had more than 3 mm invasion. No 
disease relapse was observed after median follow up 
of 69 months .Nine women attempted to conceive; 
and10 pregnancies occurred in 6 of these 
patients .There were 9 live infants and one 
miscarriage. 
There are no specific guidelines for follow up 
surveillance after radical trachelectomy. In general, 
it is recommended to obtain cervical cytology, every 
3 or 4 months for the first 3 years and every 6 
months for the next 2 years. Colposcopy with or 
without endocervical curettage is recommended 
when cytology is abnormal. Singh et al (38) 
reviewed 197 cytological specimens’ from 32 
patients and reported false positive result in 2% of 
smears, was most often due to presence of atypical 
endometrial cells. However, in 2 of these cases, 
cytology identified recurrences long before they 
were clinically apparent. Follow up cytology can be 
truly normal but frequently reported as abnormal, so 
good communication with an experienced 
cytopathologists becomes very important and critical 
to avoid an unnecessary surgery. The decision to 
perform definite hysterectomy in patients once they 
have completed their family plan should be done on 
an individual basis. 
Transposition of the Ovary Ovarian 
transposition is a procedure in which the ovaries and 
their blood supply are detached from the uterus and 
transposed to an area above the pelvis in the 
paracolic area. Retro uterine bilateral ovarian 
transposition has been performed in patients with 
hematologic malignancies i.e. lymphoma or 
Hodgkin disease (39, 40). 
The rationale of this procedure is to protect the 
ovaries from direct radiation exposure, hereby 
preserving ovarian function for future surrogate 
pregnancy by in vitro fertilization. Only a few cases 
of occult metastatic cervical cancer to ovaries have 
been reported, most involving non-squamous lesions 
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(41). Ovarian transposition can be performed in high 
risk early stage cervical cancer patients treated with 
radical hysterectomy that will require post-operative 
radiation or chemoradiation. Potential risks include 
direct injury to ovarian vessels, torsion, cystic 
changes, and mid-cycle extra pelvic (abdominal) 
pain. Unfortunately, some of the published papers 
lack detailed descriptions of the surgical procedures 
and precautions taken to protect ovaries from 
scattered radiation. Several studies (41-48) 
demonstrated that 50-70% of patients who undergo 
ovarian transposition retain their ovarian function 
after radiation therapy at a median follow up of 35 
months (Table 2). Successful surrogate pregnancies 
involving patients who had hysterectomy and pelvic 
radiation have also been reported (49, 50).
  
Table 1 Reported pregnancy out come from radical trachelectomy  
 
Authors No of Pregnancies 
        
Fetal losses 
 
Birth Rate 
 
Covens A, et al (23). 5 2 (40%) 3 (60%) 
Dargent D, et al (24). 25* 12 (48%) 13 (52%) 
Shepherd J, et al (25). 14 5 (36%) 9 (64%) 
Burnett AF, et al (26). 3 ( 1 twin) 1 (33.3) 3 (66.7%) 
Plante M, et al (27). 
Boss FA, et al (28). 
Total 
50* 
161 
258 
10 (20%) 
47(29%)  
 77 
36 (72%) 
107 (70%) 
181 
* Include cases that were pregnant at the time of procedure 
 
Table 2 Ovarian transposition in cervical cancer patients treated with pelvic radiation 
 
Authors No of Patients Stage of disease Preservation of  
Ovarian Function 
Morice, et al (41). 25  IB-IIA** 60% 
Hodel, et al (42). 7 IB-IIIB 57% 
Husseinzadeh, et al 18 IB-IIIB 63% 
Chambers, et al (44) 14     IB٭٭ 71% 
Anderson, et al (45) 24     IB 17% 
Husseinzadeh, et al (46) 15 IB-IIIB 64% 
Feeny, et al (47) 28 IA-IIB 50% 
Buekers, et al (48) 24 IA-IIB 41% 
 
**No information was given regarding ovarian shielding and dosimetery 
  
Endometrial Hyperplasia and Adenocarcinoma 
Approximately 5% of women with endometrial 
cancer are younger than 40 years of age. 
Endometrial adenocarcinoma is preceded by 
complex endometrial hyperplasia with or without 
atypia. The risk of concomitant complex atypical 
endometrial hyperplasia and endometrial cancer has 
been reported to be 25% (51). Currently, the 
standard treatment of early stage endometrial 
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adenocarcinoma is total abdominal hysterectomy 
and bilateral salpingo-oophorectomy. However there 
is no specific fertility-sparing surgery for young 
women with this disease, although the survival for 
patients with stage IA is reported to be near 100% 
(52). Therefore, those patients with complex 
atypical hyperplasia or state IAG1 endometrial 
adenocarcinoma are optimal candidates for 
hormonal therapy using progestational agents. In 
fact, successful pregnancies have been reported in 
patients who were treated with progestin therapy. 
Ushijima et al (53) reported the result of a 
multicenter study in Japan. Twenty-eight patients 
having endometrial cancer (EC), presumed at stage 
IA, and 17 patients with atypical hyperplasia (AH) 
younger than 40 years of age were given an oral 
daily dose of 600 mg of medroxy progesterone 
acetate (MPA). Complete response was found in 
55% of EC patients and 82% of AH patients (overall 
CR=67%). During a 3 year follow up period, 12 
pregnancies and 7 normal deliveries were achieved.  
  Gallos et al( 54) reported the result of thirty-four 
observational studies evaluating the rate of 
regression, relapse, and live birth in 408 women 
with early-stage endometrial cancer and 151 women 
with atypical endometrial hyperplasia that received 
fertility-sparing treatment. In patients with EC there 
was a 76.2%regression rate, the relapse rate was 
40.6%, and live birth rate was 28%. For patients 
with ACH, the regression rate was 85.6%, a relapse 
rate of 26%, and a live birth rate of 26.3%.Twenty 
women were diagnosed with ovarian cancer 
(concurrent or metastatic) during follow-up (3.6%) 
and 10 progressed to higher than stage I EC (1.9%), 
from which 2 women died. 
Options for fertility preservation in young patients 
with endometrial cancer without myometrial 
invasion are limited to hormonal therapy. DeCruz et 
al. (55) reported the result of five randomized and 
29 phase II studies of hormone interventions in 
previously untreated patients with grade 1 (G1) or 
G2 endometrial cancer. The response rate for 
progestogens and the progression-free survival was 
in the range of 11-56% and 2.5-14 months, 
respectively. Higher response rates were seen in 
progesterone receptor-positive cases. 
In a review of the literature, Ramirez et al (56) 
reported that in 81 patients with G1 endometrial 
adenocarcinoma, 76% responded to hormonal 
treatment with a 12 week median time to response. 
The recurrence rate was 24% with median time to 
recurrence of 19 months. 
The intrauterine progesterone device has been 
used in patients with endometrial hyperplasia and 
early stage endometrial cancer with some success. 
Levonorgestrel–releasing intrauterine system 
(LNG-IUS) has been used in the treatment of 
endometrial hyperplasia. LNG-IUS achieved 
endometrial regression in 90% of patients by 2 years 
and 96% within one year. Regression occurred in 
92% of non-atypical and 67% of atypical 
hyperplasia (57, 58). 
In a study by Montz et al (59), using a different 
intrauterine device, complete regression in 75% of 
patients with stage I G1 endometrial cancer was 
reported. Within endometrial cancer, well 
differentiated tumors with positive progesterone 
receptors are most likely to respond to the treatment 
with progesterone. However there is some concern 
that intrauterine progesterone devices may not 
deliver a uniform dose to the total endometrial 
cavity or, undetected myometrial invasion becomes 
sanctuary of this tumor in patients with persistent 
disease (60). 
Ovarian Cancer 
Ovarian cancer commonly occurs in 
postmenopausal women with the vast majority 
having advanced disease at the time of diagnosis. 
Ovarian cancer also occurs in young women and 
there are some patients who might be more 
appropriate for fertility-sparing surgery. Those 
include stage IA epithelial ovarian cancers and 
tumors of low malignant potential, germ cell and 
sex-cord tumors. These tumors are frequently 
limited to one ovary and generally present at a very 
early stage without extra-ovarian metastasis. 
Although conservative surgery with comprehensive 
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staging is required, this should not result in sterility 
of the patient. Types of fertility-sparing surgery may 
include ovarian cystectomy or unilateral 
salpingo-oophorectomy with or without 
hysterectomy, and bilateral salpingo-oophorectomy 
without hysterectomy. In some patients with high 
grade immature teratomas, embroynal carcinomas, 
endodermal sinus tumors, and stage IA grade 3 
epithelial ovarian cancers, combination 
chemotherapy is recommended. Zanetta et al (61) 
reported reproductive function in 138 of 169 (81%) 
patients with malignant germ cell tumors in whom 
fertility-sparing surgery was performed. Of these 81 
patients (77%) received chemotherapy. During 
follow up, 12 untreated and 20 treated patients had 
total of a 55 pregnancies. Of those, 40 had term 
pregnancies, 6 had pregnancy termination, and 9 had 
pregnancy loss. Four fetal malformations were 
reported: one in a patient who did not receive 
chemotherapy and 3 in those who did. Tangir et al 
(62) also reported the reproductive function in 
patients with malignant germ cell tumors after 
conservative surgery and chemotherapy. Of 86 
patients, fertility-sparing surgery was performed on 
64 of them. Of these, 38 patients attempted 
pregnancy and 29 achieved at least one pregnancy 
(76%). There was no significant difference between 
those treated with surgery combined with 
chemotherapy versus surgery alone. Gershenson et 
al (63) reported in a series of 132 survivors of 
malignant germ cell tumors, seventy one patients 
(53.8%) had fertility-sparing surgery, and 24 
patients reported 37 children after cancer treatment 
was complete.  
Ovarian tumors of low malignant potential (LMP) or 
border line tumors are often diagnosed by incident 
after ovarian cystectomy or oophorectomy for a 
suspected benign ovarian tumor. These tumors 
account for 10-15% of all epithelial ovarian cancer. 
These patients commonly have a longer survival and 
very low recurrences rates compared to their 
invasive counterparts. The 5 year survival of 
patients with stage I tumors exceeds 95% and makes 
them excellent candidates for fertility–sparing 
surgery, as many of them will become pregnant and 
carry normal deliveries (64). Morris et al (65) 
reported the result of their study in 43 patients with 
borderline ovarian tumors. Recurrence was more 
frequent in patients who had ovarian cystectomy 
compared to those treated with oophorectomy alone 
(58% compared with 23%). After treatment, 29 of 
36 patients (81%) retained normal menstrual cycles, 
and 12 of 24 patients (50%) attempting pregnancy 
conceived 25 pregnancies. In another study reported 
by Morice et al (66), 44 patients were treated with 
conservative management. There were 17 
pregnancies, of which 13 occurred in patients with 
stage I disease and 4 occurred in patients with stage 
III disease.  
A French multi-center study (67) on fertility after 
conservative treatment of borderline ovarian tumors 
revealed that among the 360 women, 162 (45%) 
underwent conservative treatment. Regarding 
fertility after conservative treatment, 21 of the 65 
conservatively treated women (32.3%) became 
pregnant and had a total of 30 pregnancies. 
Patients with stage IA epithelial ovarian cancers 
who wish to preserve fertility could have 
conservative surgery because of reported a 5-year 
survival approaching 90% (68). Patients with a 
strong family history for ovarian and breast cancer 
or carry BRCA1, BRCA2 mutations require 
counseling regarding fertility-sparing surgery and 
my instead consider prophylactic mastectomy or 
salpingo-oophorectomy with or without 
hysterectomy when childbearing is completed. 
Successful pregnancies have been reported in 
patients with early stage invasive epithelial ovarian 
cancer who underwent fertility sparing surgery. 
Schilder et al (69) reported reproductive outcome on 
52 patients with stage I epithelial ovarian cancer: 24 
patients attempted pregnancy and 17 (71%) 
conceived. These 17 patients had 26 term deliveries 
and 5 had spontaneous pregnancy loss. The 
estimated survival was 98% at 5 years and 93% at 
10 years. 
 Morice et al (70) published the result of a 
retrospective multicenter study by two French 
groups on clinical outcome and fertility-sparing 
surgery. Of 34 eligible patients with invasive 
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epithelial ovarian cancer, 30 patients had stage IA 
disease, 3 had stage IC and one had stage IIA 
disease. Eleven patients had recurrence: 10 patients 
had invasive and one had borderline. Adjuvant 
platinum-based chemotherapy was given to 10 
patients (7 stage IA, 3 with stage >IA). Of 24 
patients without recurrences, 10 pregnancies 
occurred in 9 patients. The authors concluded that 
conservative management could safely be proposed 
in patients with stage I G1 disease. 
Malignant gestational trophoblastic tumors 
(GTDs)  
Malignant GTDs can occur after any type of 
pregnancy and commonly are treated with 
chemotherapy for GTD. Oral contraception pills are 
preferred method over intra uterine device because 
of increased risk of uterine perforation with IUD 
(71). 
 Matsui H et.al (72) reported the overall pregnancy 
outcome in the first pregnancies of 137 women 
treated with chemotherapy. There was an increased 
risk of spontaneous abortion and still birth and 
repeat mole in pregnancies occurring within 6 
months of completing 
chemotherapy compared to those conceived >12 
months (37.5% vs. 10.5%). Similar findings were 
reported by Braga, et al (73). 
Other methods of fertility –preservation  
Cryopreservation of oocyte, embryo or ovarian 
tissue is available for patients who lose complete use 
of their reproductive organs due to surgery, radiation 
or chemotherapy.  
In oocyte cryopreservation, eggs are harvested for 
future fertilization and implantation. Initial results 
with this method were disappointing due to poor 
oocyte survival, low fertilization and successful 
pregnancy rates (74). Sonmezer et al (75) reviewed 
data from 21 studies and found a mean oocyte 
survival rate of 47%, a mean fertilization rate of 
52.5%, and a mean pregnancy rate per thawed 
oocyte of 1.5%.  
However advances in freezing and thawing tech-
niques over the years have resulted in improved 
oocyte survival rate. For example use of intra-
cytoplasmic sperm injection (ICSI) overcomes zona 
hardening (76), a frequent cause of implantation 
failure. Vitrification (ultra-rapid IVF) for embryo 
freezing that uses high concentration of a 
cryoprotectant that does not result in ice formation. 
Not only does this technique produce superior 
results, but it is easier and less expensive. Yoon et al 
(77) reported a survival rate of 85.1±2.9% 
(320/364,) a fertilization rate of 74.4±3.5% 
(168/218), an implantation rate of 14.2% (17/120), 
and a pregnancy rate of 43.3% (13/30), with 
vitrification using slush nitrogen.  
Cao et al (78) also reported that vitrification was 
superior to the traditional slow-freezing method, 
leading to improve oocyte survival rates, fertilization 
rates and in vitro embryonic development. 
 Grifo et al (79) reported the result of their study on 
22 women who presented for IVF. Patients 
underwent 23 embryo transfer procedures using 
thawed, fertilized oocytes. Collected oocytes were 
cryopreserved either by the slow-freezing or 
vitrification method. Fourteen women became 
pregnant; one miscarried and 10 delivered 13 viable 
infants (9 singleton and 4 twins), for a cumulative 
delivered /pregnancy rate of 57%. In this cohort ,the 
oocyte survival rate was 92% with fertility rate of 
72%.These result was not significantly different 
from in age-matched controls using fresh, nonfrozen 
autologous or donor oocytes during a similar time 
period. 
Rienzi et al (80) conducted an observational 
longitudinal cohort multicentric study to investigate 
the efficacy and reproducibility of oocyte 
cryopreservation outcomes in IVF/ICSI cycles. 
Oocyte survival from cryopreservation was 
84.7%.The rate of fertilization and subsequent 
development to top-quality embryos of oocytes 
subjected to ICSI was 75.2 and 48.1%, respectively. 
In 450 patients there were a total of 128 deliveries 
(28.4%) with 147 live infants from 929 transferred 
embryos (15.8%). They concluded that oocyte 
vitrification was an efficient and reliable approach, 
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with consistent results. 
Embryo cryopreservation is the most established 
and among the most widely available options for 
fertility preservation. It is also commonly used in 
conjunction with in vitro fertilization (IVF) which 
requires ovarian stimulation, oocyte retrieval, and 
fertilization. 
Embryo cryopreservation has some advantages 
for those who are interested in preserving fertility. It 
provides reassurance that the patient will have some 
potential to conceive and have a child. It also 
provides some assurance that it has no adverse effect 
on implantation of embryo or the outcome of 
pregnancy (81).  
The greatest concern of using this method is the 
high estrogen level required for ovarian stimulation 
particularly in patients with hormone- sensitive 
tumors such as endometrial and breast cancer. 
Another major concern is delay in the initiation of 
cancer treatment (82). Recent studies showed a 
successful ovarian stimulation using letrozole and 
gonadotropins which is associated with reduced 
estrogen level in patients with endometrial and 
breast cancer (83) 
Oktay et al (84) reported the results of a 
prospective controlled study comparing ovarian 
stimulation with tamoxifen and letrozole. Cancer 
recurrence rate was similar in both groups and did 
not appear to be increased, regardless of stage of the 
cancer. The study concluded that the Letrozole- IVF 
protocol was preferable for ovarian stimulation in 
those with breast and endometrial cancers because 
of lower peak estrogen (E2) level. 
Duo to the large number of primordial follicles 
ovarian cortical tissue, cryopreservation can be 
performed without requiring ovarian stimulation and 
delaying the initiation of cancer treatment. At 
present, cryopreservation of ovarian tissue is a 
promising option for the female cancer patient that 
also offers an excellent chance of fertility 
preservation. Cryopreservation of ovarian cortical 
strips has emerged in recent years as an easy, fast, 
and inexpensive technique (85). In particular it is the 
preferred method for prepubertal and premenarcheal 
patients receiving chemotherapy or pelvic radiation 
(86, 87).  
Orthotopic and heterotropic ovarian 
transplantation is an additional option in the hands 
of an experienced surgeon. However major concern 
of ovarian transplantation is the potential risk 
transplanted tissue to harbor malignant cells leading 
to disease recurrence (88, 89). 
 Additionally, transplantation of ovarian tissue to a 
different microenvironment  may raise concern that 
the oocyte quality might be compromised due to 
temperature differences on those sites that may 
interfere with follicular development and IVF for 
pregnancy (90). 
Natural pregnancy and live birth have been achieved 
by orthotopic transplantation of both fresh and 
frozen ovarian tissue where the fallopian tubes are 
present and patent. As a site of transplantation, 
peritoneal tissue appears to be superior to 
subcutaneous tissue due to more effective 
neovascularization and less follicular loss in the 
peritoneal tissue. Heterotropic autotransplantation is 
less invasive; it permits easy access to the 
transplanted tissue for monitoring follicular 
development in the event of reoperation and costs 
less than orthotopic transplantation (91, 92).  
Conclusion 
Earlier detection and more effective treatment 
strategies have significantly improved survival in 
patients with gynecologic cancer. As a result, there 
has been increasing attention toward patients’ 
quality of Life, including preservation of 
childbearing potential for young women. 
Traditionally, the surgical treatment of cervical, 
endometrial and ovarian cancers had involved the 
removal of reproductive organs, despite of its impact 
on fertility regardless of patient’s desire. Today, one 
can offer conservative surgery to a selected young 
patients affected by early stage gynecologic cancer, 
not only for planning in future pregnancies but also 
to maintain psychosexual wellbeing.  
Patients should be informed that fertility-sparing 
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surgery may not always be the right choice for their 
disease and could significantly impact the rate of 
disease control or remission. Other fertility 
preservation options such as oocyte or embryo 
cryopreservation and ovarian transplantation are 
also available. As a last resort they might choose 
adoption as an alternative option.  
To maximize patients’ understanding about their 
treatment and future fertility, a multidisciplinary 
approach and close collaboration between other 
related disciplines such as gynecologic oncology, 
maternal-fetal medicine, infertility and reproductive 
endocrinology, psychology, and social worker is 
required to ensure a successful outcome in these 
patients. 
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